ATE552825T1 - Flüssige orale zusammensetzungen - Google Patents

Flüssige orale zusammensetzungen

Info

Publication number
ATE552825T1
ATE552825T1 AT07732588T AT07732588T ATE552825T1 AT E552825 T1 ATE552825 T1 AT E552825T1 AT 07732588 T AT07732588 T AT 07732588T AT 07732588 T AT07732588 T AT 07732588T AT E552825 T1 ATE552825 T1 AT E552825T1
Authority
AT
Austria
Prior art keywords
aqueous suspension
simvastatin
agent
oral compositions
liquid oral
Prior art date
Application number
AT07732588T
Other languages
English (en)
Inventor
Phillip Driver
Original Assignee
Rosemont Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosemont Pharmaceuticals Ltd filed Critical Rosemont Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE552825T1 publication Critical patent/ATE552825T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A63—SPORTS; GAMES; AMUSEMENTS
    • A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
    • A63B21/00—Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices
    • A63B21/02—Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices using resilient force-resisters
    • A—HUMAN NECESSITIES
    • A63—SPORTS; GAMES; AMUSEMENTS
    • A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
    • A63B2225/00—Miscellaneous features of sport apparatus, devices or equipment
    • A63B2225/09—Adjustable dimensions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Education & Sports Medicine (AREA)
AT07732588T 2006-04-26 2007-04-26 Flüssige orale zusammensetzungen ATE552825T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74565306P 2006-04-26 2006-04-26
PCT/GB2007/001552 WO2007125339A1 (en) 2006-04-26 2007-04-26 Liquid oral compositions

Publications (1)

Publication Number Publication Date
ATE552825T1 true ATE552825T1 (de) 2012-04-15

Family

ID=38520565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07732588T ATE552825T1 (de) 2006-04-26 2007-04-26 Flüssige orale zusammensetzungen

Country Status (13)

Country Link
US (2) US9597289B2 (de)
EP (1) EP2018153B1 (de)
JP (1) JP2009534459A (de)
CN (1) CN101431982A (de)
AT (1) ATE552825T1 (de)
AU (1) AU2007245410A1 (de)
CY (1) CY1112917T1 (de)
DK (1) DK2018153T3 (de)
ES (1) ES2385752T3 (de)
PL (1) PL2018153T3 (de)
PT (1) PT2018153E (de)
SI (1) SI2018153T1 (de)
WO (1) WO2007125339A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007245410A1 (en) * 2006-04-26 2007-11-08 Rosemont Pharmaceuticals Ltd Liquid oral compositions
GB2497728A (en) * 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
CN104586761A (zh) * 2013-10-30 2015-05-06 上海信谊药厂有限公司 辛伐他汀纳米混悬剂及其制备方法
JP6832195B2 (ja) * 2016-03-03 2021-02-24 ライオン株式会社 経口液剤及び経口固形剤
EP3468606A1 (de) 2016-06-08 2019-04-17 FTF Pharma Private Limited Neuartige pharmazeutische zusammensetzung aus einer lipidsenkenden verbindung
GB201704687D0 (en) 2017-03-24 2017-05-10 Wockhardt Uk Ltd Pharmaceutical composition of simvastatin or salt thereof
CN108403630A (zh) * 2018-05-31 2018-08-17 佛山市南海东方澳龙制药有限公司 混悬剂及其制备方法
CN110812326B (zh) * 2019-11-04 2022-04-22 黑龙江省农业科学院畜牧兽医分院 一种辛伐他汀混悬乳剂及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
KR20040029459A (ko) 1995-11-02 2004-04-06 워너-램버트 캄파니 엘엘씨 지질 농도를 조절하는 제약 조성물 및 방법
DE19541260A1 (de) * 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US20050038102A1 (en) 1997-10-14 2005-02-17 Brigham And Womens Hospital Upregulation of type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
EP0940395A1 (de) * 1998-03-05 1999-09-08 Synthon B.V. Verfahren zur Erzeugung von Simvatarin in und/oder deren Derivate
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
CA2240983A1 (en) * 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
US20010006656A1 (en) 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
US6696086B1 (en) * 1999-09-10 2004-02-24 Lek Pharmaceuticals D.D. Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
AU2127500A (en) * 1999-11-11 2001-06-06 Biocon India Limited Process for manufacturing simvastatin and the novel intermediates
FR2801508B1 (fr) 1999-11-29 2003-11-14 Oreal Utilisation d'inhibiteurs d'hmg coa-reductase pour le traitement de la seborrhee
US6534537B2 (en) * 2000-01-07 2003-03-18 Kenneth Weisman Use of HMG-COA reductase inhibitors to prevent and treat BPH
DE60030483T2 (de) * 2000-03-30 2007-04-26 Cheil Jedang Corp. Ein verfahren zur herstellung von simvastatin
US6806290B2 (en) * 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
IL154068A0 (en) * 2000-07-27 2003-07-31 Teva Pharma Highly purified simvastatin compositions
DE10057648A1 (de) 2000-11-21 2002-06-06 Univ Jw Goethe Frankfurt Main Verwendung von Inhibitoren von 3-Hydroxyl-3-methylglutaryl-Coenzym-A-Reduktase
CA2433285C (en) 2000-12-14 2009-06-23 Sankyo Company, Limited Blood lipid ameliorating composition
JP2004524260A (ja) * 2001-02-27 2004-08-12 チョン クン ダン ファーマスーティカル コーポレイション シンバスタチンの改善された製造方法
JP2004535370A (ja) * 2001-03-05 2004-11-25 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 味をマスクした液体製薬学的組成物
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
US6797831B2 (en) * 2001-05-18 2004-09-28 Aurobindo Pharma Limited Process for lactonization to produce simvastatin
SI21234A (sl) * 2001-05-18 2003-12-31 Aurobindo Pharma Limited Postopek laktonizacije za proizvodnjo izredno čistega simvastatina
EP1395254B1 (de) 2001-06-12 2007-04-04 Galephar M/F Oral anzuwendende arzneizusammensetzung enthaltend ein statinderivat
FR2827770B1 (fr) 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
US20030060501A1 (en) 2001-09-19 2003-03-27 Francois Mach Facilitating tissue grafts with statins (HMG-COa reductase inhibitors)
US6709600B2 (en) 2001-09-21 2004-03-23 The Regents Of The University Of California Method for removing organic liquids from aqueous solutions and mixtures
US20040142902A1 (en) 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US20040018248A1 (en) 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
AU2002364146A1 (en) * 2001-12-20 2003-07-09 Pharmacia Corporation Pharmaceutical suspension for oral administration
US20030162827A1 (en) 2002-01-30 2003-08-28 Suresh Venkataram HMG CoA reductase inhibiting composition, method of preparation thereof and method for competitively inhibiting HMG CoA reductase using such composition
ES2192988B1 (es) 2002-02-28 2005-02-16 Jose Manuel Quesada Gomez Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.
US7074825B2 (en) 2002-03-07 2006-07-11 Huanbiao Mo Composition and method for treating cancer
US6603022B1 (en) * 2002-05-10 2003-08-05 Biocon India Limited Process for manufacturing Simvastatin and novel intermediates thereof
AU2003245313A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20050182106A1 (en) 2002-07-11 2005-08-18 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocysteine
WO2004006919A1 (ja) * 2002-07-11 2004-01-22 Sankyo Company, Limited 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
US20050182036A1 (en) 2002-08-02 2005-08-18 Sankyo Company, Limited Medicinal composition containing an HMG-CoA reductase inhibitor
US20050187204A1 (en) 2002-08-08 2005-08-25 Sankyo Company, Limited Medicinal composition for lowering blood lipid level
WO2004021972A2 (en) 2002-09-03 2004-03-18 Biovail Laboratories, Inc. Pharmaceuticals formulations and methods for modified release of statin drugs
AU2003270487A1 (en) 2002-09-11 2004-04-30 The Board Of Trustees Of The University Of Arkansas Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin
CN100486572C (zh) 2002-11-04 2009-05-13 饶品昌 他汀类药物新剂型
EP1592679A2 (de) * 2003-02-11 2005-11-09 Plus Chemicals B.V. Verfahren zur herstellung von simvastatin unter kontrolle des simvastatin-dimer-gehalts
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
EP1510208A1 (de) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
TW200529821A (en) 2003-11-05 2005-09-16 Teva Pharma Simvastatin formulations and methods of making same
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
EP1563837A1 (de) 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolämische Zusammensetzungen enthaltend ein Statin und ein Antiflatulenzmittel
DE602005008935D1 (de) 2004-04-26 2008-09-25 Alcon Inc Statine zur behandlung von okularer hypertonie und glaukom
US20050267197A1 (en) 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
JP2006022039A (ja) * 2004-07-08 2006-01-26 Towa Yakuhin Kk 高い安定性を有するシンバスタチン固形製剤
ES2255426B1 (es) 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
AU2007245410A1 (en) * 2006-04-26 2007-11-08 Rosemont Pharmaceuticals Ltd Liquid oral compositions
CN101888829A (zh) * 2007-10-09 2010-11-17 诺瓦提斯公司 缬沙坦的药物制剂

Also Published As

Publication number Publication date
EP2018153B1 (de) 2012-04-11
EP2018153A1 (de) 2009-01-28
AU2007245410A1 (en) 2007-11-08
ES2385752T3 (es) 2012-07-31
CY1112917T1 (el) 2016-04-13
US9597289B2 (en) 2017-03-21
WO2007125339A1 (en) 2007-11-08
DK2018153T3 (da) 2012-07-23
US20090311330A1 (en) 2009-12-17
PL2018153T3 (pl) 2012-09-28
CN101431982A (zh) 2009-05-13
SI2018153T1 (sl) 2012-08-31
PT2018153E (pt) 2012-07-04
US20170143669A1 (en) 2017-05-25
JP2009534459A (ja) 2009-09-24
US10300041B2 (en) 2019-05-28

Similar Documents

Publication Publication Date Title
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
MX2009004767A (es) Preparacion liquida que comprende un complejo de pimobendan y ciclodextrina.
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
JP2010529999A5 (de)
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
TW200600118A (en) Pharmaceutical suspension composition
MX2010003923A (es) Formulacion farmaceutica de valsartan.
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
MX348936B (es) Formulaciones de antibioticos, dosis unitarias, equipos y metodos.
JP2009531457A5 (de)
TW200716202A (en) Pediatric formulation of topiramate
ES2720954T3 (es) Formulaciones estabilizadas de estatina
WO2009064681A3 (en) Liquid compositions comprising valsartan
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
WO2008114859A1 (ja) ピラゾール誘導体を含有する医薬組成物
RS52150B (en) PELLETS CONTAINING VENLAFAKSIN HYDROCHLORIDE
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
CY1120050T1 (el) Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων
MX2014009660A (es) Formulacion de anticuerpo anti-selectina p.
FI3554474T3 (fi) Mikafungiinikoostumuksia
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
PE20130180A1 (es) Soluciones farmaceuticas orales que comprenden telbivudina